Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Sulfa	O
(Sulfonamide	O
Antibiotics)	O
/	O
Avelox	O
/	O
Lipitor	O
/	O
Elavil	O
/	O
Motrin	O
/	O
morphine	O
/	O
ellipta	O
/	O
Penicillins	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Severe	O
Aortic	O
Stenosis	O
s/p	O
TAVR	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
TAVR	O
(___)	O
PPM	O
(___)	O
History	O
of	O
Present	O
Illness:	O
Ms.	O
___	O
is	O
a	O
___	O
y/o	O
F	O
w/	O
severe	O
aortic	O
stenosis,	O
afib	O
(on	O
Elliquis),	O
non-obstructive	O
CAD,	O
hypothyroidism,	O
breast	O
cancer	O
s/p	O
lumpectomy,	O
hypertension,	O
and	O
HLD,	O
who	O
presents	O
now	O
for	O
TAVR.	O
Of	O
note,	O
patient	O
was	O
recently	O
admitted	O
from	O
___	O
to	O
___	O
for	O
pre-syncope	O
and	O
afib	O
w/	O
RVR.	O
She	O
was	O
found	O
to	O
have	O
severe	O
AS,	O
and	O
her	O
symptoms	O
were	O
thought	O
secondary	O
to	O
this.	O
She	O
underwent	O
emergent	O
TAVR	O
work-up,	O
but	O
unfortunately	O
the	O
day	O
she	O
was	O
scheduled	O
to	O
undergo	O
the	O
procedure	O
received	O
apixiban.	O
Thus,	O
she	O
instead	O
was	O
discharged	O
with	O
plan	O
for	O
TAVR	O
___.	O
Patient	O
states	O
since	O
discharge	O
she	O
has	O
essentially	O
been	O
home	O
bound	O
due	O
to	O
her	O
significant	O
dyspnea.	O
She	O
denies	O
any	O
chest	O
pain	O
or	O
palpitations.	O
She	O
presented	O
for	O
her	O
procedure	O
as	O
scheduled	O
today.	O
Given	O
her	O
baseline	O
RBBB,	O
she	O
was	O
felt	O
high	O
risk	O
for	O
arrhythmias,	O
and	O
thus	O
a	O
temporary	O
pacemaker	O
was	O
placed	O
prior	O
to	O
the	O
procedure.	O
The	O
procedure	O
itself	O
was	O
unremarkable,	O
with	O
successful	O
placement	O
of	O
her	O
prosthesis.	O
She	O
did,	O
however,	O
develop	O
___	O
Mobitz	O
Type	O
1,	O
and	O
thus	O
required	O
pacing.	O
Past	O
Medical	O
History:	O
Cardiac	O
History:	O
-	O
Afib	O
-	O
Non-obstructive	O
CAD	O
-	O
HTN	O
-	O
HLD	O
Other	O
PMH:	O
-	O
Breast	O
cancer	O
s/p	O
lumpectomy	O
-	O
Fibromyalgia	O
-	O
GERD	O
-	O
Hypothyroidism	O
Social	O
History:	O
___	O
Family	O
History:	O
There	O
was	O
no	O
family	O
history	O
of	O
stroke,	O
diabetes,	O
hypertension,	O
heart	O
disease.	O
He	O
mother	O
died	O
at	O
___	O
of	O
an	O
aneurysm	O
and	O
was	O
a	O
smoker.	O
Her	O
father	O
died	O
at	O
___	O
of	O
dementia.	B-Dementia
Physical	O
Exam:	O
ADMISSION	O
PHYSICAL	O
EXAMINATION:	O
==================================	O
VS:	O
Reviewed	O
in	O
Metavision	O
GENERAL:	O
Elderly	O
appearing	O
female	O
in	O
no	O
acute	O
distress	O
HEENT:	O
Normocephalic,	O
atraumatic.	O
Pacemaker	O
temporary	O
wire	O
in	O
place	O
over	O
RIJ.	O
CARDIAC:	O
Regular	O
rate	O
and	O
rhythm,	O
loud	O
S2	O
LUNGS:	O
No	O
increased	O
work	O
of	O
breathing,	O
CTAB	O
ABDOMEN:	O
Soft,	O
non-tender,	O
non-distended.	O
EXTREMITIES:	O
Warm,	O
well	O
perfused.	O
No	O
lower	O
extremity	O
edema.	O
Bandage	O
over	O
right	O
femoral	O
area,	O
c/d/I	O
PULSES:	O
Distal	O
pulses	O
palpable	O
and	O
symmetric.	O
NEURO:	O
CNII-XII	O
grossly	O
intact	O
DISCHARGE	O
PHYSICAL	O
EXAM:	O
=================================	O
VS:	O
T	O
97.6	O
BP	O
120/54	O
HR	O
78	O
RR	O
18	O
SpO2	O
100%	O
RA	O
Wt:	O
157.6	O
lbs	O
PE:	O
Gen:	O
Patient	O
is	O
comfortable,	O
in	O
no	O
acute	O
distress.	O
HEENT:	O
Face	O
symmetrical,	O
trachea	O
midline.	O
Neuro:	O
A/Ox3.	B-Delirium
Speaking	O
in	O
complete,	O
coherent	O
sentences.	O
No	O
focal	O
deficits.	O
Pulm:	O
Breathing	O
unlabored.	O
Breath	O
sounds	O
clear	O
bilaterally.	O
Cardiac:	O
No	O
JVD.	O
No	O
thrills	O
or	O
bruits	O
heard	O
on	O
carotids	O
bilaterally.	O
S1,	O
S2	O
RRR.	O
No	O
splitting	O
of	O
heart	O
sounds,	O
murmurs,	O
S3,	O
S4	O
or	O
friction	O
rubs	O
heard.	O
Vasc:	O
No	O
edema	O
noted	O
in	O
bilateral	O
upper	O
or	O
lower	O
extremities.	O
No	O
pigmentation	O
changes	O
noted	O
in	O
bilateral	O
upper	O
or	O
lower	O
extremities.	O
Skin	O
dry,	O
warm.	O
Bilateral	O
radial,	O
___	O
pulses	O
palpable	O
2+.	O
Integ:	O
Bilateral	O
femoral	O
access	O
sites	O
soft,	O
non-tender	O
with	O
no	O
drainage,	O
swelling	O
or	O
hematoma	O
noted.	O
Both	O
sites	O
are	O
open	O
to	O
air.	O
No	O
bruits	O
auscultated.	O
L	O
chest	O
incision	O
with	O
dry	O
gauze	O
dressing.	O
No	O
swelling,	O
drainage,	O
redness	O
or	O
hematoma	O
noted.	O
Abd:	O
Rounded,	O
soft,	O
non-tender.	O
Pertinent	O
Results:	O
ADMISSION	O
LABS	O
==================	O
___	O
06:25PM	O
BLOOD	O
WBC-5.3	O
RBC-3.59*	O
Hgb-9.3*	O
Hct-30.1*	O
MCV-84	O
MCH-25.9*	O
MCHC-30.9*	O
RDW-14.8	O
RDWSD-45.1	O
Plt	O
___	O
___	O
06:25PM	O
BLOOD	O
___	O
PTT-50.2*	O
___	O
___	O
06:25PM	O
BLOOD	O
Glucose-90	O
UreaN-14	O
Creat-0.8	O
Na-142	O
K-4.5	O
Cl-109*	O
HCO3-23	O
AnGap-10	O
___	O
06:25PM	O
BLOOD	O
Calcium-8.8	O
Phos-3.3	O
Mg-1.8	O
DISCHARGE	O
LABS:	O
==============	O
___	O
WBC-10.6*	O
RBC-3.92	O
Hgb-10.3*	O
Hct-33.2*	O
MCV-85	O
MCH-26.3	O
MCHC-31.0*	O
RDW-15.3	O
RDWSD-46.4*	O
Plt	O
___	O
___	O
___	O
___	O
UreaN-19	O
Creat-0.9	O
Na-142	O
K-3.8	O
Cl-105	O
HCO3-23	O
AnGap-14	O
Mg-2.0	O
IMAGING	O
==========	O
TTE	O
___	O
CONCLUSION:	O
Pre-TAVR:	O
Overall	O
left	O
ventricular	O
systolic	O
function	O
is	O
normal.	O
The	O
visually	O
estimated	O
left	O
ventricular	O
ejection	O
fraction	O
is	O
55-60%.	O
The	O
aortic	O
valve	O
leaflets	O
are	O
severely	O
thickened.	O
There	O
is	O
SEVERE	O
aortic	O
valve	O
stenosis	O
(valve	O
area	O
1.0	O
cm2	O
or	O
less).	O
There	O
is	O
trace	O
aortic	O
regurgitation.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened.	O
There	O
is	O
mild	O
[1+]	O
mitral	O
regurgitation.	O
POST-PROCEDURE:	O
The	O
Evolut	O
Pro	O
TAVR	O
prosthesis	O
is	O
well	O
seated	O
with	O
normal	O
leaflet	O
motion	O
and	O
normal	O
gradient.	O
There	O
is	O
a	O
paravalvular	O
jet	O
of	O
trace	O
aortic	O
regurgitation.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
TTE	O
___	O
CONCLUSION:	O
The	O
left	O
atrial	O
volume	O
index	O
is	O
moderately	O
increased.	O
The	O
estimated	O
right	O
atrial	O
pressure	O
is	O
___	O
mmHg.	O
There	O
is	O
moderate	O
symmetric	O
left	O
ventricular	O
hypertrophy	O
with	O
a	O
normal	O
cavity	O
size.	O
There	O
is	O
normal	O
regional	O
and	O
global	O
left	O
ventricular	O
systolic	O
function.	O
Quantitative	O
biplane	O
left	O
ventricular	O
ejection	O
fraction	O
is	O
65%	O
(normal	O
54-73%).	O
There	O
is	O
no	O
resting	O
left	O
ventricular	O
outflow	O
tract	O
gradient.	O
Normal	O
right	O
ventricular	O
cavity	O
size	O
with	O
normal	O
free	O
wall	O
motion.	O
The	O
aortic	O
sinus	O
diameter	O
is	O
normal	O
for	O
gender	O
with	O
normal	O
ascending	O
aorta	O
diameter	O
for	O
gender.	O
The	O
aortic	O
arch	O
diameter	O
is	O
normal	O
with	O
a	O
mildly	O
dilated	O
descending	O
aorta.	O
An	O
Evolut	O
Pro	O
aortic	O
valve	O
bioprosthesis	O
is	O
present.	O
The	O
prosthesis	O
is	O
well	O
seated	O
with	O
normal	O
gradient.	O
There	O
is	O
trace	O
aortic	O
regurgitation.	O
The	O
mitral	O
valve	O
leaflets	O
are	O
mildly	O
thickened	O
with	O
no	O
mitral	O
valve	O
prolapse.	O
There	O
is	O
moderate	O
mitral	O
annular	O
calcification.	O
There	O
is	O
mild	O
[1+]	O
mitral	O
regurgitation,	O
with	O
evidence	O
of	O
flow	O
in	O
both	O
systolic	O
and	O
diastole	O
likely	O
related	O
to	O
prolonged	O
PR	O
interval/AV	O
delay.	O
Due	O
to	O
acoustic	O
shadowing,	O
the	O
severity	O
of	O
mitral	O
regurgitation	O
could	O
be	O
UNDERestimated.	O
The	O
pulmonic	O
valve	O
leaflets	O
are	O
normal.	O
There	O
is	O
mild	O
pulmonic	O
regurgitation.	O
The	O
tricuspid	O
valve	O
leaflets	O
appear	O
structurally	O
normal.	O
There	O
is	O
mild	O
[1+]	O
tricuspid	O
regurgitation	O
with	O
evidence	O
of	O
diastolic	O
tricuspid	O
regurgitation.	O
Due	O
to	O
acoustic	O
shadowing,	O
the	O
severity	O
of	O
tricuspid	O
regurgitation	O
may	O
be	O
UNDERestimated.	O
There	O
is	O
mild	O
pulmonary	O
artery	O
systolic	O
hypertension.	O
There	O
is	O
no	O
pericardial	O
effusion.	O
Compared	O
with	O
the	O
prior	O
TTE	O
(images	O
reviewed)	O
of	O
___	O
,	O
the	O
aortic	O
valve	O
has	O
been	O
replaced	O
with	O
a	O
normal	O
functioning	O
TAVR	O
with	O
trivial	O
paravalvular	O
regurgitation.	O
Diastolic	O
mitral	O
and	O
tricuspid	O
regurgitation	O
are	O
present	O
and	O
pacing	O
wire	O
is	O
new.	O
EP	O
Report	O
___:	O
	O
Successful	O
implant	O
of	O
a	O
dual	O
chamber	O
PPM	O
via	O
the	O
left	O
cephalic	O
vein.	O
	O
Successful	O
removal	O
of	O
the	O
RIJ	O
temp	O
wire.	O
	O
No	O
complications.	O
Brief	O
Hospital	O
Course:	O
Ms.	O
___	O
is	O
an	O
___	O
y/o	O
F	O
w/	O
afib,	O
HLD,	O
and	O
HTN,	O
presenting	O
now	O
for	O
TAVR	O
c/b	O
Mobitz	O
type	O
1	O
3:2	O
block.	O
#CORONARIES:	O
40%	O
proximal	O
LAD	O
stenosis	O
(___)	O
#PUMP:	O
EF	O
55-60%	O
#RHYTHM:	O
V	O
paced	O
rate	O
60-85	O
bpm	O
ACUTE	O
ISSUES:	O
=============	O
#.	O
Mobitz	O
Type	O
I,	O
3:2	O
Block	O
Noted	O
on	O
post-TAVR	O
EKG	O
to	O
have	O
new	O
conduction	O
defect	O
c/w	O
Mobitz	O
I.	O
Arrhythmia	O
likely	O
in	O
setting	O
of	O
procedure	O
given	O
increased	O
risk	O
in	O
setting	O
of	O
her	O
baseline	O
RBBB.	O
Temp	O
wire	O
placed	O
by	O
EP,	O
on	O
VVI.	O
Permanent	O
dual	O
chamber	O
PPM	O
placed	O
and	O
temp	O
wire	O
removed	O
___	O
with	O
no	O
complications.	O
Site	O
stable.	O
Interrogation	O
and	O
post-op	O
CXR	O
were	O
WNL.	O
Home	O
beta	O
blockers	O
and	O
CCB	O
restarted.	O
#.	O
Severe	O
Aortic	O
Stenosis	O
s/p	O
TAVR	O
Pre-procedure,	O
aortic	O
valve	O
area	O
1.0	O
cm2	O
or	O
less.	O
Underwent	O
TAVR	O
with	O
placement	O
of	O
29	O
mm	O
EVOLUT	O
Pro	O
prosthesis	O
on	O
___.	O
Per	O
post-procedure	O
echo,	O
TAVR	O
prosthesis	O
appears	O
to	O
be	O
in	O
appropriate	O
location	O
with	O
trace	O
aortic	O
regurgitation	O
(AV	O
peak/mean	O
gradients:	O
16	O
mmHg/8	O
mmHg),	O
___	O
1.8	O
cm2.	O
Anticoagulation:	O
Asa,	O
Apixaban	O
#.	O
Atrial	O
Fibrillation	O
-	O
RC:	O
Continue	O
Sotalol	O
and	O
Verapamil	O
-	O
Anticoagulation:	O
Continue	O
Apixaban	O
#.	O
Normocytic	O
Hypochromic	O
Anemia	O
Hemoglobin	O
decreased	O
from	O
10.5	O
to	O
9.3	O
post-TAVR.	O
Stable	O
on	O
dc	O
(10.3).	O
No	O
overt	O
evidence	O
of	O
bleeding,	O
catheter	O
insertion	O
sites	O
appeared	O
stable.	O
CHRONIC	O
ISSUES:	O
===============	O
#.	O
HTN:	O
clinically	O
stable	O
-	O
Continue	O
Losartan	O
#.	O
HLD:	O
FLP	O
unknown	O
-	O
Continue	O
Ezetimibe	O
#.	O
Hypothyroidism	O
-	O
Continue	O
Levothyroxine	O
#.	O
GERD	O
-	O
Continue	O
ranitidine	O
#	O
Dispo:	O
Home	O
today	O
with	O
___	O
services	O
-	O
Device	O
clinic	O
follow	O
up	O
in	O
___:	O
___	O
@	O
1040,	O
then	O
___	O
thereafter	O
with	O
___,	O
NP	O
___	O
@	O
1400	O
-	O
Structural	O
follow	O
up	O
with	O
concurrent	O
TTE:	O
___	O
@	O
1400,	O
1500	O
-	O
PCP	O
___	O
Cardiology	O
Dr.	O
___	O
ups	O
requested	O
for	O
___are	O
Connections.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Apixaban	O
5	O
mg	O
PO	O
BID	O
2.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
3.	O
Ezetimibe	O
10	O
mg	O
PO	O
QPM	O
4.	O
Levothyroxine	O
Sodium	O
125	O
mcg	O
PO	O
DAILY	O
5.	O
Losartan	O
Potassium	O
25	O
mg	O
PO	O
DAILY	O
6.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
7.	O
Oxazepam	O
30	O
mg	O
PO	O
QHS	O
8.	O
Ranitidine	O
150	O
mg	O
PO	O
DAILY:PRN	O
GERD	O
9.	O
Senna	O
8.6	O
mg	O
PO	O
QHS	O
10.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
11.	O
Ascorbic	O
Acid	O
___	O
mg	O
PO	O
DAILY	O
12.	O
Bacillus	O
coagulans	O
1	O
billion	O
cell	O
oral	O
DAILY	O
13.	O
Sotalol	O
80	O
mg	O
PO	O
BID	O
14.	O
Verapamil	O
SR	O
120	O
mg	O
PO	O
Q12H	O
Discharge	O
Medications:	O
1.	O
Aspirin	O
81	O
mg	O
PO	O
DAILY	O
2.	O
Apixaban	O
5	O
mg	O
PO	O
BID	O
3.	O
Ascorbic	O
Acid	O
___	O
mg	O
PO	O
DAILY	O
4.	O
Bacillus	O
coagulans	O
1	O
billion	O
cell	O
oral	O
DAILY	O
5.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
6.	O
Ezetimibe	O
10	O
mg	O
PO	O
QPM	O
7.	O
Levothyroxine	O
Sodium	O
125	O
mcg	O
PO	O
DAILY	O
8.	O
Losartan	O
Potassium	O
25	O
mg	O
PO	O
DAILY	O
9.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
10.	O
Oxazepam	O
30	O
mg	O
PO	O
QHS	O
11.	O
Ranitidine	O
150	O
mg	O
PO	O
DAILY:PRN	O
GERD	O
12.	O
Senna	O
8.6	O
mg	O
PO	O
QHS	O
13.	O
Sotalol	O
80	O
mg	O
PO	O
BID	O
14.	O
Verapamil	O
SR	O
120	O
mg	O
PO	O
Q12H	O
15.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
Discharge	O
Disposition:	O
Home	O
With	O
Service	B-Has_carers
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Severe	O
Aortic	O
Stenosis	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
VS:	O
T	O
97.6	O
BP	O
120/54	O
HR	O
78	O
RR	O
18	O
SpO2	O
100%	O
RA	O
PE:	O
Gen:	O
Patient	O
is	O
comfortable,	O
in	O
no	O
acute	O
distress.	O
HEENT:	O
Face	O
symmetrical,	O
trachea	O
midline.	O
Neuro:	O
A/Ox3.	B-Delirium
Speaking	O
in	O
complete,	O
coherent	O
sentences.	O
No	O
focal	O
deficits.	O
Pulm:	O
Breathing	O
unlabored.	O
Breath	O
sounds	O
clear	O
bilaterally.	O
Cardiac:	O
No	O
JVD.	O
No	O
thrills	O
or	O
bruits	O
heard	O
on	O
carotids	O
bilaterally.	O
S1,	O
S2	O
RRR.	O
No	O
splitting	O
of	O
heart	O
sounds,	O
murmurs,	O
S3,	O
S4	O
or	O
friction	O
rubs	O
heard.	O
Vasc:	O
No	O
edema	O
noted	O
in	O
bilateral	O
upper	O
or	O
lower	O
extremities.	O
No	O
pigmentation	O
changes	O
noted	O
in	O
bilateral	O
upper	O
or	O
lower	O
extremities.	O
Skin	O
dry,	O
warm.	O
Bilateral	O
radial,	O
___	O
pulses	O
palpable	O
2+.	O
Integ:	O
Bilateral	O
femoral	O
access	O
sites	O
soft,	O
non-tender	O
with	O
no	O
drainage,	O
swelling	O
or	O
hematoma	O
noted.	O
Both	O
sites	O
are	O
open	O
to	O
air.	O
No	O
bruits	O
auscultated.	O
L	O
chest	O
incision	O
with	O
dry	O
gauze	O
dressing.	O
No	O
swelling,	O
drainage,	O
redness	O
or	O
hematoma	O
noted.	O
Abd:	O
Rounded,	O
soft,	O
non-tender.	O
Discharge	O
Instructions:	O
You	O
were	O
admitted	O
for	O
a	O
trans	O
catheter	O
aortic	O
valve	O
replacement	O
(TAVR)	O
to	O
treat	O
your	O
aortic	O
valve	O
stenosis	O
which	O
was	O
done	O
on	O
___.	O
By	O
repairing	O
the	O
valve	O
your	O
heart	O
can	O
pump	O
blood	O
more	O
easily	O
and	O
your	O
dyspnea	O
should	O
improve.	O
After	O
your	O
TAVR	O
procedure	O
you	O
had	O
a	O
slow	O
heart	O
rhythm	O
and	O
required	O
a	O
pacemaker	O
implant.	O
Activity	O
restrictions	O
and	O
information	O
regarding	O
care	O
of	O
the	O
procedure	O
site	O
on	O
your	O
chest	O
are	O
included	O
in	O
your	O
discharge	O
instructions.	O
An	O
appointment	O
was	O
made	O
for	O
you	O
to	O
return	O
in	O
1	O
week	O
to	O
the	O
device	O
clinic	O
to	O
check	O
the	O
wound.	O
This	O
was	O
made	O
in	O
___	O
because	O
there	O
was	O
no	O
available	O
appointments	O
in	O
___.	O
Subsequent	O
follow	O
ups	O
for	O
your	O
pacemaker	O
will	O
be	O
in	O
___.	O
It	O
is	O
very	O
important	O
to	O
take	O
all	O
of	O
your	O
heart	O
healthy	O
medications.	O
In	O
particular,	O
you	O
are	O
now	O
taking	O
Aspirin	O
and	O
Apixaban	O
(Eliquis).	O
A	O
prescription	O
for	O
Aspirin	O
was	O
sent	O
to	O
your	O
local	O
___.	O
These	O
medications	O
help	O
to	O
prevent	O
blood	O
clots	O
from	O
forming	O
on	O
the	O
new	O
valve.	O
If	O
you	O
stop	O
these	O
medications	O
or	O
miss	O
___	O
dose,	O
you	O
risk	O
causing	O
a	O
blood	O
clot	O
forming	O
on	O
your	O
new	O
valve.	O
This	O
could	O
cause	O
it	O
to	O
malfunction	O
and	O
it	O
may	O
be	O
life	O
threatening.	O
Please	O
do	O
not	O
stop	O
taking	O
Aspirin	O
and	O
Apixaban	O
without	O
taking	O
to	O
your	O
heart	O
doctor,	O
even	O
if	O
another	O
doctor	O
tells	O
you	O
to	O
stop	O
the	O
medications.	O
You	O
will	O
need	O
prophylactic	O
antibiotics	O
prior	O
to	O
any	O
dental	O
procedure.	O
Please	O
inform	O
your	O
dentist	O
about	O
your	O
recent	O
cardiac	O
procedure,	O
and	O
obtain	O
a	O
prescription	O
from	O
your	O
doctor	O
before	O
any	O
procedure.	O
Please	O
weigh	O
yourself	O
every	O
day	O
in	O
the	O
morning	O
after	O
you	O
go	O
to	O
the	O
bathroom	O
and	O
before	O
you	O
get	O
dressed.	O
If	O
your	O
weight	O
goes	O
up	O
by	O
more	O
than	O
3	O
lbs	O
in	O
1	O
day	O
or	O
more	O
than	O
5	O
lbs	O
in	O
3	O
days,	O
please	O
call	O
your	O
heart	O
doctor	O
or	O
your	O
primary	O
care	O
doctor	O
and	O
alert	O
them	O
to	O
this	O
change.	O
Your	O
weight	O
at	O
discharge	O
is	O
158	O
lbs.	O
We	O
have	O
made	O
changes	O
to	O
your	O
medication	O
list,	O
so	O
please	O
make	O
sure	O
to	O
take	O
your	O
medications	O
as	O
directed.	O
You	O
will	O
also	O
need	O
to	O
have	O
close	O
follow	O
up	O
with	O
your	O
heart	O
doctor	O
and	O
your	O
primary	O
care	O
doctor.	O
If	O
you	O
were	O
given	O
any	O
prescriptions	O
on	O
discharge,	O
any	O
future	O
refills	O
will	O
need	O
to	O
be	O
authorized	O
by	O
your	O
outpatient	O
providers,	O
primary	O
care	O
or	O
cardiologist.	O
If	O
you	O
have	O
any	O
urgent	O
questions	O
that	O
are	O
related	O
to	O
your	O
recovery	O
from	O
your	O
procedure	O
or	O
are	O
experiencing	O
any	O
symptoms	O
that	O
are	O
concerning	O
to	O
you	O
and	O
you	O
think	O
you	O
may	O
need	O
to	O
return	O
to	O
the	O
hospital,	O
please	O
call	O
the	O
___	O
Heart	O
Line	O
at	O
___	O
to	O
speak	O
to	O
a	O
cardiologist	O
or	O
cardiac	O
nurse	O
practitioner.	O
It	O
has	O
been	O
a	O
pleasure	O
to	O
have	O
participated	O
in	O
your	O
care	O
and	O
we	O
wish	O
you	O
the	O
best	O
with	O
your	O
health.	O
Followup	O
Instructions:	O
___	O

